Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Sep 21;15(9):e45692.
doi: 10.7759/cureus.45692. eCollection 2023 Sep.

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature

Aditya Mahadevan  1 , Brian Warnecke  2 , Elaine Chiao  1 , Nellie Nafissi  2 , Kritisha Parajuli  3 , Nejina Rijal  4 , Ritesh Parajuli  2
Affiliations
Case Reports

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature

Aditya Mahadevan et al. Cureus. .

Abstract

A chemical burn resulting from luteinizing hormone-releasing hormone agonists (LHRHa) is a rare adverse effect that has not been well-documented in prior literature. In this case report, we report a partial-thickness burn that developed following a single subcutaneous injection of goserelin. To our knowledge, this is the first description of goserelin-induced chemical burn in the literature. The importance of early identification and treatment of LHRHa-associated cutaneous reactions must be highlighted to ensure optimal oncologic management and patient comfort.

Keywords: aromatase inhibitor; chemical burn; goserelin; ovarian suppression; rash.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. 9x10 cm region of erythema and induration on the right lower abdominal wall
Figure 2
Figure 2. 9x10 cm area of erythema with small overlying fluid-filled vesicle
See this image and copyright information in PMC

References

    1. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet Lond Engl. 2015;3:1341–1352. - PubMed
    1. Ovarian function suppression with luteinizing hormone-releasing hormone agonists for the treatment of hormone receptor-positive early breast cancer in premenopausal women. Lu YS, Wong A, Kim HJ. Front Oncol. 2021;11:700722. - PMC - PubMed
    1. Treatment of breast cancer with gonadotropin-releasing hormone analogs. Huerta-Reyes M, Maya-Núñez G, Pérez-Solis MA, López-Muñoz E, Guillén N, Olivo-Marin JC, Aguilar-Rojas A. Front Oncol. 2019;9:943. - PMC - PubMed
    1. Managing side effects in adjuvant endocrine therapy for breast cancer. Condorelli R, Vaz-Luis I. Expert Rev Anticancer Ther. 2018;18:1101–1112. - PubMed
    1. Effects of ovarian ablation or suppression in premenopausal breast cancer: a meta-analysis of randomized controlled trials. Zhang P, Li CZ, Jiao GM, et al. Eur J Surg Oncol. 2017;1:1161–1172. - PubMed

Publication types

LinkOut - more resources